Hormonal
Treatment of NAFLD with specific pharmacological agents, particularly pioglitazone and GLP-1 receptor agonists, can improve liver histology and potentially reduce cardiovascular risk, although large RCTs focusing on CVD outcomes are still needed.
If lifestyle changes are insufficient, medications like pioglitazone or GLP-1 agonists may be considered. They have shown efficacy in improving liver inflammation and fibrosis in clinical trials. Discuss with your doctor if these are appropriate for your cardiovascular risk profile.
Table 1... Glitazones (pioglitazone, rosiglitazone)... Liver inflammation: Improved... Liver fibrosis: Improved... GLP-1 receptor agonists... Liver fat: Improved... Liver inflammation: Improved... Liver fibrosis: Improved.
Why this rating
Based on Phase 2 RCTs for liver outcomes; CVD outcomes from these specific drugs are less established in large trials compared to general NAFLD risk.
Source
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher et al. · Gut · 2020
DOI 10.1136/gutjnl-2020-320622
More from this paper
- Non-alcoholic fatty liver disease (NAFLD) is independently associated with a significantly increased risk of major cardiovascular disease (CVD) events, including fatal and non-fatal outcomes, with risk magnitude increasing with the severity of liver fibrosis.Good
- Low-grade systemic inflammation, driven by hepatic cytokine production, visceral adipose tissue, and gut microbiota metabolites (like TMAO), is a key pathophysiological mechanism linking NAFLD to cardiovascular disease and arrhythmias.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →